169 related articles for article (PubMed ID: 26781523)
1. Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis.
Stein A; Schwenke C; Folprecht G; Arnold D
Clin Colorectal Cancer; 2016 Jun; 15(2):e29-39. PubMed ID: 26781523
[TBL] [Abstract][Full Text] [Related]
2. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.
Salvatore L; Bria E; Sperduti I; Hinke A; Hegewisch-Becker S; Aparicio T; Le Malicot K; Boige V; Koeberle D; Baertschi D; Dietrich D; Tortora G; Arnold D
Cancer Treat Rev; 2021 Jun; 97():102202. PubMed ID: 33838596
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
Goey KKH; Elias SG; Hinke A; van Oijen MGH; Punt CJA; Hegewisch-Becker S; Arnold D; Koopman M
Br J Cancer; 2017 Dec; 117(12):1768-1776. PubMed ID: 29123255
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis.
Ma H; Wu X; Tao M; Tang N; Li Y; Zhang X; Zhou Q
Medicine (Baltimore); 2019 Dec; 98(50):e18227. PubMed ID: 31852082
[TBL] [Abstract][Full Text] [Related]
6. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T
JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer.
Zhao L; Wang J; Li H; Che J; Cao B
Oncotarget; 2016 May; 7(22):33418-28. PubMed ID: 27072579
[TBL] [Abstract][Full Text] [Related]
8. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
Manfredi S; Turpin A; Malka D; Barbier E; Laurent-Puig P; Zaanan A; Dahan L; Lièvre A; Phelip JM; Michel P; Hautefeuille V; Legoux JL; Lepage C; Tougeron D; Aparicio T
Dig Liver Dis; 2020 Oct; 52(10):1143-1147. PubMed ID: 32747302
[TBL] [Abstract][Full Text] [Related]
9. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Stein A; Atanackovic D; Hildebrandt B; Stübs P; Brugger W; Hapke G; Steffens CC; Illerhaus G; Bluemner E; Stöhlmacher J; Bokemeyer C
Br J Cancer; 2015 Sep; 113(6):872-7. PubMed ID: 26335608
[TBL] [Abstract][Full Text] [Related]
10. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
Moriwaki T; Gosho M; Sugaya A; Yamada T; Yamamoto Y; Hyodo I
Cancer Res Treat; 2021 Jul; 53(3):703-713. PubMed ID: 33285056
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
Wolff RA; Fuchs M; Di Bartolomeo M; Hossain AM; Stoffregen C; Nicol S; Heinemann V
Cancer; 2012 Sep; 118(17):4132-8. PubMed ID: 22213153
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).
Aparicio T; Ghiringhelli F; Boige V; Le Malicot K; Taieb J; Bouché O; Phelip JM; François E; Borel C; Faroux R; Dahan L; Jacquot S; Genet D; Khemissa F; Suc E; Desseigne F; Texereau P; Lepage C; Bennouna J;
J Clin Oncol; 2018 Mar; 36(7):674-681. PubMed ID: 29346040
[TBL] [Abstract][Full Text] [Related]
13. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
14. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
[TBL] [Abstract][Full Text] [Related]
15. Maintenance based Bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: A meta-analysis of randomized clinical trials.
Tamburini E; Rudnas B; Santelmo C; Drudi F; Gianni L; Nicoletti SV; Ridolfi C; Tassinari D
Crit Rev Oncol Hematol; 2016 Aug; 104():115-23. PubMed ID: 27338848
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
17. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
18. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy-single-institution experience.
Fedyanin M; Tryakin A; Vybarava A; Chekini D; Pokataev I; Sekhina O; Gordeev S; Aliev V; Tjulandin S
Med Oncol; 2015 Jan; 32(1):429. PubMed ID: 25491142
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis.
Kaveh S; Ebrahimi P; Rezapour A; Mozafari M; Sayehmiri K
Int J Clin Pharm; 2019 Feb; 41(1):30-41. PubMed ID: 30610548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
